Search

Your search keyword '"Chotivanich, Kesinee"' showing total 564 results
Start Over Author "Chotivanich, Kesinee"
564 results on '"Chotivanich, Kesinee"'

2. A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults

Author

Hanboonkunupakarn, Borimas, Mukaka, Mavuto, Jittamala, Podjanee, Poovorawan, Kittiyod, Pongsuwan, Pongphaya, Stockdale, Lisa, Provstgaard-Morys, Samuel, Chotivanich, Kesinee, Tarning, Joel, Hoglund, Richard M., Chimjinda, Natenapa, Ewer, Katie, Ramos-Lopez, Fernando, Day, Nicholas P. J., Dondorp, Arjen M., Hill, Adrian V., White, Nicholas J., von Seidlein, Lorenz, and Pukrittayakamee, Sasithon

Published
2024
Full Text
View/download PDF

3. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Author

Luvira, Viravarn, Schilling, William H. K., Jittamala, Podjanee, Watson, James A., Boyd, Simon, Siripoon, Tanaya, Ngamprasertchai, Thundon, Almeida, Pedro J., Ekkapongpisit, Maneerat, Cruz, Cintia, Callery, James J., Singh, Shivani, Tuntipaiboontana, Runch, Kruabkontho, Varaporn, Ngernseng, Thatsanun, Tubprasert, Jaruwan, Abdad, Mohammad Yazid, Keayarsa, Srisuda, Madmanee, Wanassanan, Aguiar, Renato S., Santos, Franciele M., Hanboonkunupakarn, Pongtorn, Hanboonkunupakarn, Borimas, Poovorawan, Kittiyod, Imwong, Mallika, Taylor, Walter R. J., Chotivanich, Vasin, Chotivanich, Kesinee, Pukrittayakamee, Sasithon, Dondorp, Arjen M., Day, Nicholas P. J., Teixeira, Mauro M., Piyaphanee, Watcharapong, Phumratanaprapin, Weerapong, and White, Nicholas J.

Published
2024
Full Text
View/download PDF

6. Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Author

Schilling, William H. K., Mukaka, Mavuto, Callery, James J., Llewelyn, Martin J., Cruz, Cintia V., Dhorda, Mehul, Ngernseng, Thatsanun, Waithira, Naomi, Ekkapongpisit, Maneerat, Watson, James A., Chandna, Arjun, Nelwan, Erni J., Hamers, Raph L., Etyang, Anthony, Beg, Mohammad Asim, Sow, Samba, Yavo, William, Allabi, Aurel Constant, Basnyat, Buddha, Sharma, Sanjib Kumar, Amofa-Sekyi, Modupe, Yonga, Paul, Adler, Amanda, Yuentrakul, Prayoon, Cope, Tanya, Thaipadungpanit, Janjira, Rienpradub, Panuvit, Imwong, Mallika, Abdad, Mohammad Yazid, Blacksell, Stuart D., Tarning, Joel, Goudjo, Frejus Faustin, Dossou, Ange D., Konaté-Touré, Abibatou, Assi, Serge-Brice, Ouffoué, Kra, Nasronudin, Nasronudin, Rachman, Brian Eka, Romadhon, Pradana Zaky, Dewanto, Didi Darmahadi, Heryana, Made Oka, Novi, Theresia, Pasaribu, Ayodhia Pitaloka, Mutiara, Mutiara, Nasution, Miranda Putri Rahayu, Khairunnisa, Khairunnisa, Dalimunthe, Fauzan Azima, Airlangga, Eka, Fahrezzy, Akmal, Subronto, Yanri, Ananda, Nur Rahmi, Rahardjani, Mutia, Rimainar, Atika, Lucinde, Ruth Khadembu, Timbwa, Molline, Onyango, Otieno Edwin, Agutu, Clara, Akech, Samuel, Hamaluba, Mainga, Kipyego, Jairus, Ngachi, Obadiah, Haidara, Fadima Cheick, Traoré, Oumar Y., Diarra, François, Khanal, Basudha, Dahal, Piyush, Shrestha, Suchita, Rijal, Samita, Kabore, Youssouf, Adehossi, Eric, Guindo, Ousmane, Qamar, Farah Naz, Kazi, Abdul Momin, Woodrow, Charles J., Laird, Steven, Cheeba, Maina, Ayles, Helen, Cheah, Phaik Yeong, Taylor, Walter R. J., Batty, Elizabeth M., Chotivanich, Kesinee, Pukrittayakamee, Sasithon, Phumratanaprapin, Weerapong, von Seidlein, Lorenz, Dondorp, Arjen, Day, Nicholas P. J., and White, Nicholas J.

Subjects
Hydroxychloroquine -- Testing, Chloroquine -- Testing, Biological sciences
Abstract

Background Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507. Interpretation In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs. Trial registration ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947., Author(s): William H. K. Schilling 1,2,*, Mavuto Mukaka 1,2, James J. Callery 1,2, Martin J. Llewelyn 3,4, Cintia V. Cruz 1,2, Mehul Dhorda 1,2, Thatsanun Ngernseng 1, Naomi Waithira 1,2, [...]

Published
2024
Full Text
View/download PDF

8. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Author

Callery, James, Cruz, Cintia, Taylor, Walter, Thaipadungpanit, Janjira, Ekkapongpisit, Maneerat, Kruabkontho, Varaporn, Ngernseng, Thatsanun, Tubprasert, Jaruwan, Abdad, Mohammad, Keayarsa, Srisuda, Anunsittichai, Orawan, Hongsuwan, Maliwan, Singhaboot, Yutatirat, Madmanee, Wanassanan, Tuntipaiboontana, Runch, Promsongsil, Amornrat, Saroj, Manisaree, Suwannasin, Kanokon, Beer, Ellen, Asawasriworanan, Tanatchakorn, Blacksell, Stuart, Panapipat, Salwaluk, Waithira, Naomi, Tarning, Joel, Tanglakmankhong, Nuttakan, Almeida, Pedro J, Aguiar, Renato S, Ascencao, Fernando, Esper, Lisia, Vongsouvath, Manivanh, Phommasone, Koukeo, Dubot-Pérès, Audrey, Vidhamaly, Sisouphanh, Chingsanoon, Ammala, Bisayher, Sixiong, Chommanam, Danoy, Evans, Terry, Vidhamaly, Vayouly, Boutthasavong, Latsaniphone, Vongphachanh, Susath, Potaporn, Manus, Srisubat, Attasit, Loharjun, Bootsakorn, Beg, M Asim, Kazi, Abdul Momin, Qamar, Farah, Ghanchi, Najia, Mahmood, Syed Faisal, Hanboonkunupakarn, Pongtorn, Sookprome, Sakol, Chotivanich, Vasin, Ruksakul, Wiroj, Sangketchon, Chunlanee, Wongnak, Phrutsamon, Schilling, William H K, Jittamala, Podjanee, Boyd, Simon, Luvira, Viravarn, Siripoon, Tanaya, Ngamprasertchai, Thundon, Batty, Elizabeth M, Singh, Shivani, Kouhathong, Jindarat, Pagornrat, Watcharee, Khanthagan, Patpannee, Hanboonkunupakarn, Borimas, Poovorawan, Kittiyod, Mayxay, Mayfong, Chotivanich, Kesinee, Imwong, Mallika, Pukrittayakamee, Sasithon, Ashley, Elizabeth A, Dondorp, Arjen M, Day, Nicholas P J, Teixeira, Mauro M, Piyaphanee, Watcharapong, Phumratanaprapin, Weerapong, White, Nicholas J, and Watson, James A

Published
2024
Full Text
View/download PDF

9. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Author

White, Nicholas J, Schilling, William HK, Phumratanaprapin, Weerapong, Luvira, Viravarn, Callery, James J, Day, Nicholas PJ, Pukrittayakamee, Sasithon, Boyd, Simon, Cruz, Cintia, Dondorp, Arjen M, Taylor, Walter RJ, Watson, James A, Piyaphanee, Watcharapong, Poovorawan, Kittiyod, Ngamprasertchai, Thundon, Siripoon, Tanaya, Hanboonkunupakarn, Borimas, Chotivanich, Kesinee, Jittamala, Podjanee, Imwong, Mallika, Thaipadungpanit, Janjira, Ekkapongpisit, Maneerat, Kruabkontho, Varaporn, Ngernseng, Thatsanun, Tubprasert, Jaruwan, Abdad, Mohammad Yazid, Batty, Elizabeth M, Singh, Shivani, Chotivanich, Vasin, Ruksakul, Wiroj, Sangketchon, Chunlanee, Hanboonkunupakarn, Pongtorn, Sookprome, Sakol, Teixeira, Mauro, Almeida, Pedro J, Aguiar, Renato S, Santos, Franciele, Ashley, Elizabeth, Vongsouvath, Manivanh, Phommasone, Koukeo, Dubot-Pérès, Audrey, Vidhamaly, Sisouphanh, Chingsanoon, Ammala, Bisayher, Sixiong, Chommanam, Danoy, Evans, Terry John, Vidhamaly, Vayouly, Boutthasavong, Latsaniphone, Mayxay, Mayfong, Potaporn, Manus, Srisubat, Attasit, Loharjun, Bootsakorn, Schilling, William H K, Saroj, Manisaree, Tanglakmankhong, Nuttakan, Madmanee, Wanassanan, Kouhathong, Jindarat, Suwannasin, Kanokon, Pagornrat, Watcharee, Piaraksa, Nattaporn, Taylor, Walter R J, Day, Nicholas P J, and Teixeira, Mauro M

Published
2024
Full Text
View/download PDF

13. Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials

Author

Phommasone, Koukeo, van Leth, Frank, Peto, Thomas J, Landier, Jordi, Nguyen, Thuy-Nhien, Tripura, Rupam, Pongvongsa, Tiengkham, Lwin, Khin Maung, Kajeechiwa, Ladda, Thwin, May Myo, Parker, Daniel M, Wiladphaingern, Jacher, Nosten, Suphak, Proux, Stephane, Nguon, Chea, Davoeung, Chan, Rekol, Huy, Adhikari, Bipin, Promnarate, Cholrawee, Chotivanich, Kesinee, Hanboonkunupakarn, Borimas, Jittmala, Podjanee, Cheah, Phaik Yeong, Dhorda, Mehul, Imwong, Mallika, Mukaka, Mavuto, Peerawaranun, Pimnara, Pukrittayakamee, Sasithon, Newton, Paul N, Thwaites, Guy E, Day, Nicholas PJ, Mayxay, Mayfong, Hien, Tran Tinh, Nosten, Francois H, Cobelens, Frank, Dondorp, Arjen M, White, Nicholas J, and von Seidlein, Lorenz

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Vector-Borne Diseases, Prevention, Clinical Trials and Supportive Activities, Infectious Diseases, Clinical Research, Malaria, Infection, Good Health and Well Being, Adolescent, Adult, Antimalarials, Artemisinins, Cambodia, Child, Female, Humans, Malaria, Falciparum, Malaria, Vivax, Male, Mass Drug Administration, Myanmar, Prevalence, Primaquine, Quinolines, Recurrence, Treatment Outcome, Vietnam, Young Adult, General Science & Technology
Abstract

BackgroundMass administrations of antimalarial drugs (MDA) have reduced the incidence and prevalence of P. falciparum infections in a trial in the Greater Mekong Subregion. Here we assess the impact of the MDA on P. vivax infections.MethodsBetween May 2013 and July 2017, four villages in each Myanmar, Vietnam, Cambodia and Lao PDR were selected based on high prevalence of P. falciparum infections. Eight of the 16 villages were randomly assigned to receive MDA consisting of three-monthly rounds of three-day courses of dihydroartemisinin-piperaquine and, except in Cambodia, a single low-dose of primaquine. Cross-sectional surveys were conducted at quarterly intervals to detect Plasmodium infections using ultrasensitive qPCR. The difference in the cumulative incidence between the groups was assessed through a discrete time survival approach, the difference in prevalence through a difference-in-difference analysis, and the difference in the number of participants with a recurrence of P. vivax infection through a mixed-effect logistic regression.Results3,790 (86%) residents in the intervention villages participated in at least one MDA round, of whom 2,520 (57%) participated in three rounds. The prevalence of P. vivax infections fell from 9.31% to 0.89% at month 3 but rebounded by six months to 5.81%. There was no evidence that the intervention reduced the cumulative incidence of P.vivax infections (95% confidence interval [CI] Odds ratio (OR): 0.29 to 1.36). Similarly, there was no evidence of MDA related reduction in the number of participants with at least one recurrent infection (OR: 0.34; 95% CI: 0.08 to 1.42).ConclusionMDA with schizontocidal drugs had a lasting effect on P. falciparum infections but only a transient effect on the prevalence of P. vivax infections. Radical cure with an 8-aminoquinoline will be needed for the rapid elimination of vivax malaria.

Published
2020

14. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.

Author

von Seidlein, Lorenz, Peto, Thomas J, Landier, Jordi, Nguyen, Thuy-Nhien, Tripura, Rupam, Phommasone, Koukeo, Pongvongsa, Tiengkham, Lwin, Khin Maung, Keereecharoen, Lilly, Kajeechiwa, Ladda, Thwin, May Myo, Parker, Daniel M, Wiladphaingern, Jacher, Nosten, Suphak, Proux, Stephane, Corbel, Vincent, Tuong-Vy, Nguyen, Phuc-Nhi, Truong Le, Son, Do Hung, Huong-Thu, Pham Nguyen, Tuyen, Nguyen Thi Kim, Tien, Nguyen Thanh, Dong, Le Thanh, Hue, Dao Van, Quang, Huynh Hong, Nguon, Chea, Davoeung, Chan, Rekol, Huy, Adhikari, Bipin, Henriques, Gisela, Phongmany, Panom, Suangkanarat, Preyanan, Jeeyapant, Atthanee, Vihokhern, Benchawan, van der Pluijm, Rob W, Lubell, Yoel, White, Lisa J, Aguas, Ricardo, Promnarate, Cholrawee, Sirithiranont, Pasathorn, Malleret, Benoit, Rénia, Laurent, Onsjö, Carl, Chan, Xin Hui, Chalk, Jeremy, Miotto, Olivo, Patumrat, Krittaya, Chotivanich, Kesinee, Hanboonkunupakarn, Borimas, Jittmala, Podjanee, Kaehler, Nils, Cheah, Phaik Yeong, Pell, Christopher, Dhorda, Mehul, Imwong, Mallika, Snounou, Georges, Mukaka, Mavuto, Peerawaranun, Pimnara, Lee, Sue J, Simpson, Julie A, Pukrittayakamee, Sasithon, Singhasivanon, Pratap, Grobusch, Martin P, Cobelens, Frank, Smithuis, Frank, Newton, Paul N, Thwaites, Guy E, Day, Nicholas PJ, Mayxay, Mayfong, Hien, Tran Tinh, Nosten, Francois H, Dondorp, Arjen M, and White, Nicholas J

Subjects
Humans, Malaria, Falciparum, Antimalarials, Cluster Analysis, Cross-Over Studies, Drug Resistance, Multiple, Adolescent, Adult, Child, Asia, Southeastern, Female, Male, Young Adult, Disease Eradication, Mass Drug Administration, Malaria, Falciparum, Drug Resistance, Multiple, Asia, Southeastern, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThe emergence and spread of multidrug-resistant Plasmodium falciparum in the Greater Mekong Subregion (GMS) threatens global malaria elimination efforts. Mass drug administration (MDA), the presumptive antimalarial treatment of an entire population to clear the subclinical parasite reservoir, is a strategy to accelerate malaria elimination. We report a cluster randomised trial to assess the effectiveness of dihydroartemisinin-piperaquine (DP) MDA in reducing falciparum malaria incidence and prevalence in 16 remote village populations in Myanmar, Vietnam, Cambodia, and the Lao People's Democratic Republic, where artemisinin resistance is prevalent.Methods and findingsAfter establishing vector control and community-based case management and following intensive community engagement, we used restricted randomisation within village pairs to select 8 villages to receive early DP MDA and 8 villages as controls for 12 months, after which the control villages received deferred DP MDA. The MDA comprised 3 monthly rounds of 3 daily doses of DP and, except in Cambodia, a single low dose of primaquine. We conducted exhaustive cross-sectional surveys of the entire population of each village at quarterly intervals using ultrasensitive quantitative PCR to detect Plasmodium infections. The study was conducted between May 2013 and July 2017. The investigators randomised 16 villages that had a total of 8,445 residents at the start of the study. Of these 8,445 residents, 4,135 (49%) residents living in 8 villages, plus an additional 288 newcomers to the villages, were randomised to receive early MDA; 3,790 out of the 4,423 (86%) participated in at least 1 MDA round, and 2,520 out of the 4,423 (57%) participated in all 3 rounds. The primary outcome, P. falciparum prevalence by month 3 (M3), fell by 92% (from 5.1% [171/3,340] to 0.4% [12/2,828]) in early MDA villages and by 29% (from 7.2% [246/3,405] to 5.1% [155/3,057]) in control villages. Over the following 9 months, the P. falciparum prevalence increased to 3.3% (96/2,881) in early MDA villages and to 6.1% (128/2,101) in control villages (adjusted incidence rate ratio 0.41 [95% CI 0.20 to 0.84]; p = 0.015). Individual protection was proportional to the number of completed MDA rounds. Of 221 participants with subclinical P. falciparum infections who participated in MDA and could be followed up, 207 (94%) cleared their infections, including 9 of 10 with artemisinin- and piperaquine-resistant infections. The DP MDAs were well tolerated; 6 severe adverse events were detected during the follow-up period, but none was attributable to the intervention.ConclusionsAdded to community-based basic malaria control measures, 3 monthly rounds of DP MDA reduced the incidence and prevalence of falciparum malaria over a 1-year period in areas affected by artemisinin resistance. P. falciparum infections returned during the follow-up period as the remaining infections spread and malaria was reintroduced from surrounding areas. Limitations of this study include a relatively small sample of villages, heterogeneity between villages, and mobility of villagers that may have limited the impact of the intervention. These results suggest that, if used as part of a comprehensive, well-organised, and well-resourced elimination programme, DP MDA can be a useful additional tool to accelerate malaria elimination.Trial registrationClinicalTrials.gov NCT01872702.

Published
2019

15. Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Author

Peto, Thomas J, Tripura, Rupam, Callery, James J, Lek, Dysoley, Nghia, Ho Dang Trung, Nguon, Chea, Thuong, Nguyen Thi Huyen, van der Pluijm, Rob W, Dung, Nguyen Thi Phuong, Sokha, Meas, Van Luong, Vo, Long, Le Thanh, Sovann, Yok, Duanguppama, Jureeporn, Waithira, Naomi, Hoglund, Richard M, Chotsiri, Palang, Chau, Nguyen Hoang, Ruecker, Andrea, Amaratunga, Chanaki, Dhorda, Mehul, Miotto, Olivo, Maude, Richard J, Rekol, Huy, Chotivanich, Kesinee, Tarning, Joel, von Seidlein, Lorenz, Imwong, Mallika, Mukaka, Mavuto, Day, Nicholas P J, Hien, Tran Tinh, White, Nicholas J, and Dondorp, Arjen M

Published
2022
Full Text
View/download PDF

18. Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response

Author

Zhu, Lei, van der Pluijm, Rob W., Kucharski, Michal, Nayak, Sourav, Tripathi, Jaishree, White, Nicholas J., Day, Nicholas P. J., Faiz, Abul, Phyo, Aung Pyae, Amaratunga, Chanaki, Lek, Dysoley, Ashley, Elizabeth A., Nosten, François, Smithuis, Frank, Ginsburg, Hagai, von Seidlein, Lorenz, Lin, Khin, Imwong, Mallika, Chotivanich, Kesinee, Mayxay, Mayfong, Dhorda, Mehul, Nguyen, Hoang Chau, Nguyen, Thuy Nhien Thanh, Miotto, Olivo, Newton, Paul N., Jittamala, Podjanee, Tripura, Rupam, Pukrittayakamee, Sasithon, Peto, Thomas J., Hien, Tran Tinh, Dondorp, Arjen M., and Bozdech, Zbynek

Published
2022
Full Text
View/download PDF

19. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial

Author

van der Pluijm, Rob W, Tripura, Rupam, Hoglund, Richard M, Phyo, Aung Pyae, Lek, Dysoley, ul Islam, Akhter, Anvikar, Anupkumar R, Satpathi, Parthasarathi, Satpathi, Sanghamitra, Behera, Prativa Kumari, Tripura, Amar, Baidya, Subrata, Onyamboko, Marie, Chau, Nguyen Hoang, Sovann, Yok, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Chutasmit, Kitipumi, Saelow, Chalermpon, Runcharern, Ratchadaporn, Kaewmok, Weerayuth, Hoa, Nhu Thi, Thanh, Ngo Viet, Hanboonkunupakarn, Borimas, Callery, James J, Mohanty, Akshaya Kumar, Heaton, James, Thant, Myo, Gantait, Kripasindhu, Ghosh, Tarapada, Amato, Roberto, Pearson, Richard D, Jacob, Christopher G, Gonçalves, Sónia, Mukaka, Mavuto, Waithira, Naomi, Woodrow, Charles J, Grobusch, Martin P, van Vugt, Michele, Fairhurst, Rick M, Cheah, Phaik Yeong, Peto, Thomas J, von Seidlein, Lorenz, Dhorda, Mehul, Maude, Richard J, Winterberg, Markus, Thuy-Nhien, Nguyen T, Kwiatkowski, Dominic P, Imwong, Mallika, Jittamala, Podjanee, Lin, Khin, Hlaing, Tin Maung, Chotivanich, Kesinee, Huy, Rekol, Fanello, Caterina, Ashley, Elizabeth, Mayxay, Mayfong, Newton, Paul N, Hien, Tran Tinh, Valeche, Neena, Smithuis, Frank, Pukrittayakamee, Sasithon, Faiz, Abul, Miotto, Olivo, Tarning, Joel, Day, Nicholas PJ, White, Nicholas J, Dondorp, Arjen M, Pyae Phyo, Aung, Thuy-Nhien, Nguyen Thanh, Valecha, Neena, and Day, Nicholas P J

Published
2020
Full Text
View/download PDF

20. Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers

Author

Pukrittayakamee, Sasithon, primary, Jittamala, Podjanee, additional, Watson, James A, additional, Hanboonkunupakarn, Borimas, additional, Leungsinsiri, Pawanrat, additional, Poovorawan, Kittiyod, additional, Chotivanich, Kesinee, additional, Bancone, Germana, additional, Chu, Cindy S, additional, Imwong, Mallika, additional, Day, Nicholas PJ, additional, Taylor, Walter RJ, additional, and White, Nicholas J, additional

Published
2024
Full Text
View/download PDF

21. Author Response: Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers

Author

Pukrittayakamee, Sasithon, primary, Jittamala, Podjanee, additional, Watson, James A, additional, Hanboonkunupakarn, Borimas, additional, Leungsinsiri, Pawanrat, additional, Poovorawan, Kittiyod, additional, Chotivanich, Kesinee, additional, Bancone, Germana, additional, Chu, Cindy S, additional, Imwong, Mallika, additional, Day, Nicholas PJ, additional, Taylor, Walter RJ, additional, and White, Nicholas J, additional

Published
2024
Full Text
View/download PDF

22. Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Author

Jittamala, Podjanee, primary, Boyd, Simon, additional, Schilling, William Henry Keith, additional, Watson, James Andrew, additional, Ngamprasertchai, Thundon, additional, Siripoon, Tanaya, additional, Luvira, Viravarn, additional, Batty, Elizabeth M, additional, Wongnak, Phrutsamon, additional, Esper, Lisia M, additional, Almeida, Pedro J, additional, Cruz, Cintia, additional, Ascencao, Fernando R, additional, Aguiar, Renato S, additional, Ghanchi, Najia K, additional, Callery, James J, additional, Singh, Shivani, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tubprasert, Jaruwan, additional, Madmanee, Wanassanan, additional, Suwannasin, Kanokon, additional, Promsongsil, Amornrat, additional, Hanboonkunupakarn, Borimas, additional, Poovorawan, Kittiyod, additional, Potaporn, Manus, additional, Srisubat, Attasit, additional, Loharjun, Bootsakorn, additional, Taylor, Walter RJ, additional, Qamar, Farah N, additional, Kazi, Abdul Momin, additional, Beg, M Asim, additional, Chommanam, Danoy, additional, Vidhamaly, Sisouphanh, additional, Chotivanich, Kesinee, additional, Imwong, Mallika, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas PJ, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, and White, Nicholas J, additional

Published
2024
Full Text
View/download PDF

23. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Author

Wongnak, Phrutsamon, primary, Schilling, William HK, additional, Jittamala, Podjanee, additional, Boyd, Simon, additional, Luvira, Viravarn, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Batty, Elizabeth M, additional, Singh, Shivani, additional, Kouhathong, Jindarat, additional, Pagornrat, Watcharee, additional, Khanthagan, Patpannee, additional, Hanboonkunupakarn, Borimas, additional, Poovorawan, Kittiyod, additional, Mayxay, Mayfong, additional, Chotivanich, Kesinee, additional, Imwong, Mallika, additional, Pukrittayakamee, Sasithon, additional, Ashley, Elizabeth A, additional, Dondorp, Arjen M, additional, Day, Nicholas PJ, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, White, Nicholas J, additional, and Watson, James A, additional

Published
2024
Full Text
View/download PDF

26. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study

Author

van der Pluijm, Rob W, Imwong, Mallika, Chau, Nguyen Hoang, Hoa, Nhu Thi, Thuy-Nhien, Nguyen Thanh, Thanh, Ngo Viet, Jittamala, Podjanee, Hanboonkunupakarn, Borimas, Chutasmit, Kitipumi, Saelow, Chalermpon, Runjarern, Ratchadaporn, Kaewmok, Weerayuth, Tripura, Rupam, Peto, Thomas J, Yok, Sovann, Suon, Seila, Sreng, Sokunthea, Mao, Sivanna, Oun, Savuth, Yen, Sovannary, Amaratunga, Chanaki, Lek, Dysoley, Huy, Rekol, Dhorda, Mehul, Chotivanich, Kesinee, Ashley, Elizabeth A, Mukaka, Mavuto, Waithira, Naomi, Cheah, Phaik Yeong, Maude, Richard J, Amato, Roberto, Pearson, Richard D, Gonçalves, Sónia, Jacob, Christopher G, Hamilton, William L, Fairhurst, Rick M, Tarning, Joel, Winterberg, Markus, Kwiatkowski, Dominic P, Pukrittayakamee, Sasithon, Hien, Tran Tinh, Day, Nicholas PJ, Miotto, Olivo, White, Nicholas J, and Dondorp, Arjen M

Published
2019
Full Text
View/download PDF

28. On-Chip Impedance Spectroscopy of Malaria-Infected Red Blood Cells.

Author

Panklang, Nitipong, Techaumnat, Boonchai, Tanthanuch, Nutthaphong, Chotivanich, Kesinee, Horprathum, Mati, and Nakano, Michihiko

Subjects
ERYTHROCYTES, IMPEDANCE spectroscopy, ELECTRIC impedance, MICROFLUIDIC devices, DISEASE management
Abstract

Malaria is a disease that affects millions of people worldwide, particularly in developing countries. The development of accurate and efficient methods for the detection of malaria-infected cells is crucial for effective disease management and control. This paper presents the electrical impedance spectroscopy (EIS) of normal and malaria-infected red blood cells. An EIS microfluidic device, comprising a microchannel and a pair of coplanar electrodes, was fabricated for single-cell measurements in a continuous manner. Based on the EIS results, the aim of this work is to discriminate Plasmodium falciparum-infected red blood cells from the normal ones. Different from typical impedance spectroscopy, our measurement was performed for the cells in a low-conductivity medium in a frequency range between 50 kHz and 800 kHz. Numerical simulation was utilized to study the suitability parameters of the microchannel and electrodes for the EIS experiment over the measurement frequencies. The measurement results have shown that by using the low-conductivity medium, we could focus on the change in the conductance caused by the presence of a cell in the sensing electrode gap. The results indicated a distinct frequency spectrum of the conductance between the normal and infected red blood cells, which can be further used for the detection of the disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency

Author

Pukrittayakamee, Sasithon, primary, Jittamala, Podjanee, additional, Watson, James A, additional, Hanboonkunupakarn, Borimas, additional, Leungsinsiri, Pawanrat, additional, Poovorawan, Kittiyod, additional, Chotivanich, Kesinee, additional, Bancone, Germana, additional, Chu, Cindy S, additional, Imwong, Mallika, additional, Day, Nicholas PJ, additional, Taylor, Walter RJ, additional, and White, Nicholas J, additional

Published
2023
Full Text
View/download PDF

33. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Author

Schilling, William H K, primary, Jittamala, Podjanee, additional, Watson, James A, additional, Boyd, Simon, additional, Luvira, Viravarn, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Batty, Elizabeth M, additional, Cruz, Cintia, additional, Callery, James J, additional, Singh, Shivani, additional, Saroj, Manisaree, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tanglakmankhong, Nuttakan, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Madmanee, Wanassanan, additional, Kouhathong, Jindarat, additional, Suwannasin, Kanokon, additional, Pagornrat, Watcharee, additional, Piaraksa, Nattaporn, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Poovorawan, Kittiyod, additional, Potaporn, Manus, additional, Srisubat, Attasit, additional, Loharjun, Bootsakorn, additional, Taylor, Walter R J, additional, Chotivanich, Vasin, additional, Chotivanich, Kesinee, additional, Imwong, Mallika, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas P J, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, White, Nicholas J, additional, Schilling, William HK, additional, Day, Nicholas PJ, additional, Taylor, Walter RJ, additional, Thaipadungpanit, Janjira, additional, Ekkapongpisit, Maneerat, additional, Ruksakul, Wiroj, additional, Sangketchon, Chunlanee, additional, Sookprome, Sakol, additional, Teixeira, Mauro, additional, Almeida, Pedro J, additional, Aguiar, Renato S, additional, Santos, Franciele, additional, Ashley, Elizabeth, additional, Vongsouvath, Manivanh, additional, Phommasone, Koukeo, additional, Dubot-Pérès, Audrey, additional, Vidhamaly, Sisouphanh, additional, Chingsanoon, Ammala, additional, Bisayher, Sixiong, additional, Chommanam, Danoy, additional, Evans, Terry John, additional, Vidhamaly, Vayouly, additional, Boutthasavong, Latsaniphone, additional, and Mayxay, Mayfong, additional

Published
2023
Full Text
View/download PDF

34. Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

Author

Jittamala, Podjanee, primary, Schilling, William H K, additional, Watson, James A, additional, Luvira, Viravarn, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Almeida, Pedro J, additional, Ekkapongpisit, Maneerat, additional, Cruz, Cintia, additional, Callery, James J, additional, Boyd, Simon, additional, Anunsittichai, Orawan, additional, Hongsuwan, Maliwan, additional, Singhaboot, Yutatirat, additional, Pagornrat, Watcharee, additional, Tuntipaiboontana, Runch, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Keayarsa, Srisuda, additional, Madmanee, Wanassanan, additional, Aguiar, Renato S, additional, Santos, Franciele M, additional, Batty, Elizabeth M, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Sookprome, Sakol, additional, Poovorawan, Kittiyod, additional, Imwong, Mallika, additional, Taylor, Walter R J, additional, Chotivanich, Vasin, additional, Sangketchon, Chunlanee, additional, Ruksakul, Wiroj, additional, Chotivanich, Kesinee, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas P J, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, and White, Nicholas J, additional

Published
2023
Full Text
View/download PDF

35. Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs

Author

Yipsirimetee, Achaporn, primary, Tipthara, Phornpimon, additional, Hanboonkunupakarn, Borimas, additional, Tripura, Rupam, additional, Lek, Dysoley, additional, Kümpornsin, Krittikorn, additional, Lee, Marcus C. S., additional, Sattabongkot, Jetsumon, additional, Dondorp, Arjen M., additional, White, Nicholas J., additional, Kobylinski, Kevin C., additional, Tarning, Joel, additional, and Chotivanich, Kesinee, additional

Published
2023
Full Text
View/download PDF

38. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

Author

Luvira, Viravarn, primary, Schilling, William HK, additional, Jittamala, Podjanee, additional, Watson, James A, additional, Boyd, Simon, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Almeida, Pedro J, additional, Ekkapongpisit, Maneerat, additional, Cruz, Cintia, additional, Callery, James J, additional, Singh, Shivani, additional, Tuntipaiboontana, Runch, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Keayarsa, Srisuda, additional, Madmanee, Wanassanan, additional, Aguiar, Renato S, additional, Santos, Franciele M, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Poovorawan, Kittiyod, additional, Imwong, Mallika, additional, Taylor, Walter RJ, additional, Chotivanich, Vasin, additional, Chotivanich, Kesinee, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas PJ, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, and White, Nicholas J, additional

Published
2023
Full Text
View/download PDF

39. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples

Author

Abdel Hamid, Muzamil Mahdi, Abdelraheem, Mohamed Hassan, Acheampong, Desmond Omane, Ahouidi, Ambroise, Ali, Mozam, Almagro-Garcia, Jacob, Amambua-Ngwa, Alfred, Amaratunga, Chanaki, Amenga-Etego, Lucas, Andagalu, Ben, Anderson, Tim, Andrianaranjaka, Voahangy, Aniebo, Ifeyinwa, Aninagyei, Enoch, Ansah, Felix, Ansah, Patrick, Apinjoh, Tobias, Arnaldo, Paulo, Ashley, Elizabeth, Auburn, Sarah, Awandare, Gordon, Ba, Hampate, Baraka, Vito, Barry, Alyssa, Bejon, Philip, Bertin, Gwladys, Boni, Maciej, Borrmann, Steffen, Bousema, Teun, Bouyou-Akotet, Marielle, Branch, Oralee, Bull, Peter, Cheah, Huch, Chindavongsa, Keobouphaphone, Chookajorn, Thanat, Chotivanich, Kesinee, Claessens, Antoine, Conway, David, Corredor, Vladimir, Courtier, Erin, Craig, Alister, d'Alessandro, Umberto, Dama, Souleymane, Day, Nicholas, Denis, Brigitte, Dhorda, Mehul, Diakite, Mahamadou, Djimde, Abdoulaye, Dolecek, Christiane, Dondorp, Arjen, Doumbia, Seydou, Drakeley, Chris, Drury, Eleanor, Duffy, Patrick, Echeverry, Diego, Egwang, Thomas, Enosse, Sonia Maria Mauricio, Erko, Berhanu, Fairhurst, Rick, Faiz, Abdul, Fanello, Caterina, Fleharty, Mark, Forbes, Matthew, Fukuda, Mark, Gamboa, Dionicia, Ghansah, Anita, Golassa, Lemu, Goncalves, Sonia, Harrison, G, Healy, Sara Anne, Hendry, Jason, Hernandez-Koutoucheva, Anastasia, Hien, Tran Tinh, Hill, Catherine, Hombhanje, Francis, Hott, Amanda, Htut, Ye, Hussein, Mazza, Imwong, Mallika, Ishengoma, Deus, Jackson, Scott, Jacob, Chris, Jeans, Julia, Johnson, Kimberly, Kamaliddin, Claire, Kamau, Edwin, Keatley, Jon, Kochakarn, Theerarat, Konate, Drissa, Konaté, Abibatou, Kone, Aminatou, Kwiatkowski, Dominic, Kyaw, Myat, Kyle, Dennis, Lawniczak, Mara, Lee, Samuel, Lemnge, Martha, Lim, Pharath, Lon, Chanthap, Loua, Kovana, Mandara, Celine, Marfurt, Jutta, Marsh, Kevin, Maude, Richard James, Mayxay, Mayfong, Maïga-Ascofaré, Oumou, Miotto, Olivo, Mita, Toshihiro, Mobegi, Victor, Mohamed, Abdelrahim Osman, Mokuolu, Olugbenga, Montgomery, Jaqui, Morang'A, Collins Misita, Mueller, Ivo, Murie, Kathryn, Newton, Paul, Ngo Duc, Thang, Nguyen, Thuy, Nguyen, Thuy-Nhien, Nguyen Thi Kim, Tuyen, Nguyen Van, Hong, Noedl, Harald, Nosten, François, Noviyanti, Rintis, Ntui, Vincent Ntui-Njock, Nzila, Alexis, Ochola-Oyier, Lynette Isabella, Ocholla, Harold, Oduro, Abraham, Omedo, Irene, Onyamboko, Marie, Ouedraogo, Jean-Bosco, Oyebola, Kolapo, Oyibo, Wellington Aghoghovwia, Pearson, Richard, Peshu, Norbert, Phyo, Aung, Plowe, Christopher, Price, Ric, Pukrittayakamee, Sasithon, Quang, Huynh Hong, Randrianarivelojosia, Milijaona, Rayner, Julian, Ringwald, Pascal, Rosanas-Urgell, Anna, Rovira-Vallbona, Eduard, Ruano-Rubio, Valentin, Ruiz, Lastenia, Saunders, David, Shayo, Alex, Siba, Peter, Simpson, Victoria, Sissoko, Mahamadou, Smith, Christen, Su, Xin-Zhuan, Sutherland, Colin, Takala-Harrison, Shannon, Talman, Arthur, Tavul, Livingstone, Thanh, Ngo Viet, Thathy, Vandana, Thu, Aung Myint, Toure, Mahamoudou, Tshefu, Antoinette, Verra, Federica, Vinetz, Joseph, Wellems, Thomas, Wendler, Jason, White, Nicholas, Whitton, Georgia, Yavo, William, van der Pluijm, Rob, MalariaGEN, University of Khartoum, University of Cape Coast [Ghana], Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), The Wellcome Trust Sanger Institute [Cambridge], London School of Hygiene and Tropical Medicine [Fajara, Gambia], London School of Hygiene and Tropical Medicine (LSHTM), National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), West African Centre for Cell Biology of Infectious Pathogens [Legon, Ghana] (WACCBIP), University of Ghana, Navrongo Health Research Centre [Navrongo, Ghana] (NHRC), Kenya Medical Research Institute (KEMRI), Texas Biomedical Research Institute [San Antonio, TX], Université d'Antananarivo, University of Buéa, Instituto Nacional de Saude [Maputo, Mozambique] (INS), Centre for Tropical Medicine and Global Health [Oxford, UK], Nuffield Department of Medicine [Oxford, UK] (Big Data Institute), University of Oxford-University of Oxford, Mahidol Oxford Tropical Medicine Research Unit (MORU), University of Oxford-Mahidol University [Bangkok]-Wellcome Trust, Menzies School of Health Research [Australia], Charles Darwin University [Australia], Nuffield Department of Clinical Medicine [Oxford], University of Oxford, Institut de Recherche pour le Développement (IRD), Laboratory of Pathogen and Host Immunity [Montpellier] (LPHI), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), and Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM)

Subjects
data resource, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], plasmodium falciparum, genomics, malaria, Medicine (miscellaneous), genomic epidemiology, General Biochemistry, Genetics and Molecular Biology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 291985.pdf (Publisher’s version ) (Open Access) We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

Published
2023
Full Text
View/download PDF

42. Author response: Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

Author

Schilling, William HK, primary, Jittamala, Podjanee, primary, Watson, James A, additional, Ekkapongpisit, Maneerat, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Luvira, Viravarn, additional, Pongwilai, Sasithorn, additional, Cruz, Cintia, additional, Callery, James J, additional, Boyd, Simon, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Piaraksa, Nattaporn, additional, Suwannasin, Kanokon, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Sookprome, Sakol, additional, Poovorawan, Kittiyod, additional, Thaipadungpanit, Janjira, additional, Blacksell, Stuart, additional, Imwong, Mallika, additional, Tarning, Joel, additional, Taylor, Walter RJ, additional, Chotivanich, Vasin, additional, Sangketchon, Chunlanee, additional, Ruksakul, Wiroj, additional, Chotivanich, Kesinee, additional, Teixeira, Mauro Martins, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas PJ, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, and White, Nicholas J, additional

Published
2023
Full Text
View/download PDF

44. Antimalarial Property of Compounds from Propolis Extract as New Antimalarial Agent Candidates: In Vitro and In Silico Analysis

Author

Sama-ae, Imran, primary, Sangkanu, Suthinee, additional, Siyadatpanah, Abolghasem, additional, Norouzi, Roghayeh, additional, Singhabut, Yuthathirat, additional, Tedasen, Aman, additional, Bhoopong, Phuangthip, additional, Daloh, Mollaya, additional, Pual, Alok K., additional, Wilairat, Polrat, additional, Chotivanich, Kesinee, additional, Pereira, Maria de Lourdes Gomes, additional, Rahmatullah, Mohammed, additional, Wiart, Christophe, additional, Singh, Indrakant, additional, and Nissapatorn, Veeranoot, additional

Published
2023
Full Text
View/download PDF

45. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples

Author

MalariaGEN, Abdel Hamid, Muzamil Mahdi, Abdelraheem, Mohamed Hassan, Acheampong, Desmond Omane, Ahouidi, Ambroise, Ali, Mozam, Almagro-Garcia, Jacob, Amambua-Ngwa, Alfred, Amaratunga, Chanaki, Amenga-Etego, Lucas, Andagalu, Ben, Anderson, Tim, Andrianaranjaka, Voahangy, Aniebo, Ifeyinwa, Aninagyei, Enoch, Ansah, Felix, Ansah, Patrick O, Apinjoh, Tobias, Arnaldo, Paulo, Ashley, Elizabeth, Auburn, Sarah, Awandare, Gordon A, Ba, Hampate, Baraka, Vito, Barry, Alyssa, Bejon, Philip, Bertin, Gwladys I, Boni, Maciej F, Borrmann, Steffen, Bousema, Teun, Bouyou-Akotet, Marielle, Branch, Oralee, Bull, Peter C, Cheah, Huch, Chindavongsa, Keobouphaphone, Chookajorn, Thanat, Chotivanich, Kesinee, Claessens, Antoine, Conway, David J, Corredor, Vladimir, Courtier, Erin, Craig, Alister, D'Alessandro, Umberto, Dama, Souleymane, Day, Nicholas, Denis, Brigitte, Dhorda, Mehul, Diakite, Mahamadou, Djimde, Abdoulaye, Dolecek, Christiane, Dondorp, Arjen, Doumbia, Seydou, Drakeley, Chris, Drury, Eleanor, Duffy, Patrick, Echeverry, Diego F, Egwang, Thomas G, Enosse, Sonia Maria Mauricio, Erko, Berhanu, Fairhurst, Rick M, Faiz, Abdul, Fanello, Caterina A, Fleharty, Mark, Forbes, Matthew, Fukuda, Mark, Gamboa, Dionicia, Ghansah, Anita, Golassa, Lemu, Goncalves, Sonia, Harrison, GL Abby, Healy, Sara Anne, Hendry, Jason A, Hernandez-Koutoucheva, Anastasia, Hien, Tran Tinh, Hill, Catherine A, Hombhanje, Francis, Hott, Amanda, Htut, Ye, Hussein, Mazza, Imwong, Mallika, Ishengoma, Deus, Jackson, Scott A, Jacob, Chris G, Jeans, Julia, Johnson, Kimberly J, Kamaliddin, Claire, Kamau, Edwin, Keatley, Jon, Kochakarn, Theerarat, Konate, Drissa S, Konaté, Abibatou, Kone, Aminatou, Kwiatkowski, Dominic P, Kyaw, Myat P, Kyle, Dennis, Lawniczak, Mara, Lee, Samuel K, Lemnge, Martha, Lim, Pharath, Lon, Chanthap, Loua, Kovana M, Mandara, Celine I, Marfurt, Jutta, Marsh, Kevin, Maude, Richard James, Mayxay, Mayfong, Maïga-Ascofaré, Oumou, Miotto, Olivo, Mita, Toshihiro, Mobegi, Victor, Mohamed, Abdelrahim Osman, Mokuolu, Olugbenga A, Montgomery, Jaqui, Morang'a, Collins Misita, Mueller, Ivo, Murie, Kathryn, Newton, Paul N, Ngo Duc, Thang, Nguyen, Thuy, Nguyen, Thuy-Nhien, Nguyen Thi Kim, Tuyen, Nguyen Van, Hong, Noedl, Harald, Nosten, Francois, Noviyanti, Rintis, Ntui, Vincent Ntui-Njock, Nzila, Alexis, Ochola-Oyier, Lynette Isabella, Ocholla, Harold, Oduro, Abraham, Omedo, Irene, Onyamboko, Marie A, Ouedraogo, Jean-Bosco, Oyebola, Kolapo, Oyibo, Wellington Aghoghovwia, Pearson, Richard, Peshu, Norbert, Phyo, Aung P, Plowe, Christopher V, Price, Ric N, Pukrittayakamee, Sasithon, Quang, Huynh Hong, Randrianarivelojosia, Milijaona, Rayner, Julian C, Ringwald, Pascal, Rosanas-Urgell, Anna, Rovira-Vallbona, Eduard, Ruano-Rubio, Valentin, Ruiz, Lastenia, Saunders, David, Shayo, Alex, Siba, Peter, Simpson, Victoria J, Sissoko, Mahamadou S, Smith, Christen, Su, Xin-Zhuan, Sutherland, Colin, Takala-Harrison, Shannon, Talman, Arthur, Tavul, Livingstone, Thanh, Ngo Viet, Thathy, Vandana, Thu, Aung Myint, Toure, Mahamoudou, Tshefu, Antoinette, Verra, Federica, Vinetz, Joseph, Wellems, Thomas E, Wendler, Jason, White, Nicholas J, Whitton, Georgia, Yavo, William, Van Der Pluijm, Rob W, Amenga-Etego, Lucas [0000-0003-4468-0506], Anderson, Tim [0000-0002-0191-0204], Ansah, Patrick O [0000-0002-3214-5621], Ashley, Elizabeth [0000-0002-7620-4822], Ba, Hampate [0000-0002-9299-5775], Baraka, Vito [0000-0001-9694-9293], Bejon, Philip [0000-0002-2135-7549], Bertin, Gwladys I [0000-0002-2218-9591], Boni, Maciej F [0000-0002-0830-9630], Bousema, Teun [0000-0003-2666-094X], Chookajorn, Thanat [0000-0003-2876-6203], Claessens, Antoine [0000-0002-4277-0914], Conway, David J [0000-0002-8711-3037], Craig, Alister [0000-0003-0914-6164], D'Alessandro, Umberto [0000-0001-6341-5009], Day, Nicholas [0000-0003-2309-1171], Diakite, Mahamadou [0000-0002-4268-8857], Djimde, Abdoulaye [0000-0003-0062-2283], Dondorp, Arjen [0000-0001-5190-2395], Drakeley, Chris [0000-0003-4863-075X], Echeverry, Diego F [0000-0003-0301-4478], Erko, Berhanu [0000-0003-1685-752X], Faiz, Abdul [0000-0002-3460-7535], Fanello, Caterina A [0000-0003-1932-9562], Gamboa, Dionicia [0000-0002-1420-7729], Golassa, Lemu [0000-0002-1216-8711], Healy, Sara Anne [0000-0003-3078-6094], Ishengoma, Deus [0000-0003-2040-3416], Jackson, Scott A [0000-0002-3172-1607], Kamaliddin, Claire [0000-0001-8198-6235], Kamau, Edwin [0000-0002-5761-7883], Konate, Drissa S [0000-0002-4177-9642], Kwiatkowski, Dominic P [0000-0002-5023-0176], Kyle, Dennis [0000-0002-0238-965X], Lawniczak, Mara [0000-0002-3006-2080], Loua, Kovana M [0000-0003-0571-0944], Marsh, Kevin [0000-0001-8377-5466], Mayxay, Mayfong [0000-0002-6056-4516], Miotto, Olivo [0000-0001-8060-6771], Mita, Toshihiro [0000-0001-8180-2344], Mobegi, Victor [0000-0002-1962-5583], Morang'a, Collins Misita [0000-0002-6988-150X], Nguyen, Thuy-Nhien [0000-0002-4101-5706], Nosten, Francois [0000-0002-7951-0745], Ntui, Vincent Ntui-Njock [0000-0002-7532-9930], Oduro, Abraham [0000-0002-4191-7419], Onyamboko, Marie A [0000-0002-7501-5931], Ouedraogo, Jean-Bosco [0000-0003-0412-8733], Oyebola, Kolapo [0000-0002-1003-2570], Pearson, Richard [0000-0002-7386-3566], Phyo, Aung P [0000-0002-0383-9624], Price, Ric N [0000-0003-2000-2874], Rayner, Julian C [0000-0002-9835-1014], Rosanas-Urgell, Anna [0000-0002-0432-5203], Shayo, Alex [0000-0002-7099-8537], Su, Xin-Zhuan [0000-0003-3246-3248], Vinetz, Joseph [0000-0001-8344-2004], Wellems, Thomas E [0000-0003-3899-8454], and Apollo - University of Cambridge Repository

Subjects
data resource, plasmodium falciparum, genomics, malaria, genomic epidemiology
Abstract

We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

Published
2023

46. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance

Author

Mok, Sachel, Ashley, Elizabeth A., Ferreira, Pedro E., Zhu, Lei, Lin, Zhaoting, Yeo, Tomas, Chotivanich, Kesinee, Imwong, Mallika, Pukrittayakamee, Sasithon, Dhorda, Mehul, Nguon, Chea, Lim, Pharath, Amaratunga, Chanaki, Suon, Seila, Hien, Tran Tinh, Htut, Ye, Faiz, M. Abul, Onyamboko, Marie A., Mayxay, Mayfong, Newton, Paul N., Tripura, Rupam, Woodrow, Charles J., Miotto, Olivo, Kwiatkowski, Dominic P., Nosten, François, Day, Nichoals P. J., Preiser, Peter R., White, Nicholas J., Dondorp, Arjen M., Fairhurst, Rick M., and Bozdech, Zbynek

Published
2015

48. Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

Author

Jittamala, Podjanee, primary, Schilling, William HK, additional, Watson, James A, additional, Luvira, Viravarn, additional, Siripoon, Tanaya, additional, Ngamprasertchai, Thundon, additional, Almeida, Pedro J, additional, Ekkapongpisit, Maneerat, additional, Cruz, Cintia, additional, Callery, James J, additional, Boyd, Simon, additional, Anunsittichai, Orawan, additional, Hongsuwan, Maliwan, additional, Singhaboot, Yutatirat, additional, Pagornrat, Watcharee, additional, Tuntipaiboontana, Runch, additional, Kruabkontho, Varaporn, additional, Ngernseng, Thatsanun, additional, Tubprasert, Jaruwan, additional, Abdad, Mohammad Yazid, additional, Keayarsa, Srisuda, additional, Madmanee, Wanassanan, additional, Aguiar, Renato S, additional, Santos, Franciele M, additional, Batty, Elizabeth M, additional, Hanboonkunupakarn, Pongtorn, additional, Hanboonkunupakarn, Borimas, additional, Sookprome, Sakol, additional, Poovorawan, Kittiyod, additional, Imwong, Mallika, additional, Taylor, Walter RJ, additional, Chotivanich, Vasin, additional, Sangketchon, Chunlanee, additional, Ruksakul, Wiroj, additional, Chotivanich, Kesinee, additional, Pukrittayakamee, Sasithon, additional, Dondorp, Arjen M, additional, Day, Nicholas PJ, additional, Teixeira, Mauro M, additional, Piyaphanee, Watcharapong, additional, Phumratanaprapin, Weerapong, additional, and White, Nicholas J, additional

Published
2022
Full Text
View/download PDF

50. Randomized Controlled Trial of Levamisole Hydrochloride as Adjunctive Therapy in Severe Falciparum Malaria With High Parasitemia

Author

Maude, Richard J., Silamut, Kamolrat, Plewes, Katherine, Charunwatthana, Prakaykaew, Ho, May, Faiz, M. Abul, Rahman, Ridwanur, Hossain, Md Amir, Hassan, Mahtab U., Yunus, Emran Bin, Hoque, Gofranul, Islam, Faridul, Ghose, Aniruddha, Hanson, Josh, Schlatter, Joel, Lacey, Rachel, Eastaugh, Alison, Taming, Joel, Lee, Sue J., White, Nicholas J., Chotivanich, Kesinee, Day, Nicholas P. J., and Dondorp, Arjen M.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results